Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 26, 2015 08:00 ET | Source: Receptos, Inc.

Receptos to Hold Fourth Quarter and Year End 2014 Financial Results Conference Call

SAN DIEGO, Feb. 26, 2015 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will review...
February 18, 2015 08:00 ET | Source: Receptos, Inc.

Receptos Announces Oral Podium Presentation at Annual Meeting of European Crohn's and Colitis Organization (ECCO)

- Detailed Results of Positive Phase 2 Trial of RPC1063 in Ulcerative Colitis to be Presented on February 21, 2015 - - Company to Host Investor Call and Webcast on February 23, 2015 - SAN DIEGO,...
February 09, 2015 08:00 ET | Source: Receptos, Inc.

Receptos to Present at Leerink Global Healthcare Conference

SAN DIEGO, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
December 22, 2014 08:00 ET | Source: Receptos, Inc.

Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis

– Following Positive Phase 2 Results, Receptos Now Enrolling Two Phase 3 Trials in Relapsing Multiple Sclerosis – – Receptos Well...
November 24, 2014 09:48 ET | Source: Receptos, Inc.

Receptos Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Completion of Underwritten Public Offering of Common Stock

SAN DIEGO, Nov. 24, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced...
November 18, 2014 20:10 ET | Source: Receptos, Inc.

Receptos Announces Pricing of Underwritten Public Offering of Common Stock

SAN DIEGO, Nov. 18, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced...
November 17, 2014 16:01 ET | Source: Receptos, Inc.

Receptos Announces Proposed Underwritten Public Offering of Common Stock

SAN DIEGO, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced...
November 06, 2014 16:01 ET | Source: Receptos, Inc.

Receptos to Present at Credit Suisse Healthcare Conference

SAN DIEGO, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
November 04, 2014 07:00 ET | Source: Receptos, Inc.

Receptos Provides Development Updates and Reports Third Quarter 2014 Financial Results

- Recent positive Phase 2 induction results for TOUCHSTONE trial of RPC1063 in ulcerative colitis (UC) support initiation of broad program in inflammatory bowel disease - - Enrollment in first...
November 03, 2014 16:01 ET | Source: Receptos, Inc.

Receptos to Present at Nomura BioPharma Conference

SAN DIEGO, Nov. 3, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...